FindTrial
Sign In

FATE-NK100

BIOLOGICAL3 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Fate Therapeutics

Conditions

Advanced Solid TumorsColorectal CancerEGFR Positive Solid TumorEpithelial Ovarian CancerFallopian Tube CancerHER2 Positive Gastric CancerHER2-positive Breast CancerHead and Neck Squamous Cell Carcinoma

Phase 1

Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML
CompletedNCT03081780
Masonic Cancer Center, University of MinnesotaRefractory Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Start: 2017-04-27End: 2020-12-01Updated: 2021-03-12
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
CompletedNCT03213964
Masonic Cancer Center, University of MinnesotaEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Start: 2017-10-19End: 2021-03-10Updated: 2021-03-12
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
CompletedNCT03319459
Fate TherapeuticsAdvanced Solid Tumors, Colorectal Cancer, EGFR Positive Solid Tumor +8
Start: 2018-01-18End: 2020-12-15Updated: 2021-11-22

Related Papers

In Vivo Persistence and Function of Adaptive NK Cell Infusions (FATE-NK100) from CMV Seropositive Haploidentical Related Donors
Biology of Blood and Marrow Transplantation2019-01-315 citations